checkedPsychopharmacology and Psychiatry Updates2026-11-13last verified 2026-11-14

is bupropion cut by about half in child-pugh b or c liver disease? the label cuts it more

verdict: undersold
the real number is bigger, or worse, than claimed
“But buproprian, in child puke BC, you should reduce the dose by about half.”

a guest, Dr. Kevin A. Severino, lecturer on addiction psychopharmacology said on Psychopharmacology and Psychiatry Updates, 2026-11-13, at 07:17. hear it in context →

the episode: Liver Disease: Buprenorphine, Methadone, and Smoking Cessation Agents (at 07:17). we link the show's own page; we do not re-host audio.

first, the part that holds

the speaker has the direction and the patient group right. the bupropion labels group child-pugh class b and c together (scores 7 to 15) and require a lower dose for that group.

what we found when we went and looked

we read two current dailymed labels, one for the once-daily extended-release (xl) form and one for the twice-daily sustained-release (sr) form. both set a hard ceiling for moderate to severe hepatic impairment (child-pugh 7 to 15). xl: "the maximum dose is 150 mg every other day." sr: "100 mg per day or 150 mg every other day." both labels give a usual target of 300 mg per day. on that basis, 150 mg every other day averages about 75 mg a day, a cut of roughly 75 percent, and the sr options are a cut of about 67 to 75 percent. the reduction is about half only if you compare it with the 150 mg starting dose. the pharmacokinetic data behind the ceiling show bupropion exposure (auc) about 3-fold higher in severe cirrhosis, which fits a reduction to about a third, not a half.

assertion by assertion

assertionverdictwhat the record says
bupropion dosing should be reduced in patients with child-pugh class b or c hepatic impairmentconfirmedboth labels we read set a lower maximum dose for moderate to severe hepatic impairment, defined as child-pugh 7 to 15. that range covers class b (7-9) and class c (10-15). this is labeled dosing, not a suggestion. [1][2]
the reduction is about halfundersoldxl label: maximum 150 mg every other day, which averages about 75 mg a day against a usual target of 300 mg a day. that is roughly a 75 percent cut, a quarter of the usual dose. sr label: maximum 100 mg a day or 150 mg every other day against a usual target of 300 mg a day, a cut of about 67 to 75 percent. the labels set this as a ceiling, not a proportional reduction. 'about half' holds only against the 150 mg starting dose, and it misses that the xl ceiling also halves how often the dose is taken. [1][2]
exposure rises substantially in severe hepatic impairment (supporting pharmacology)confirmedxl label section 12.3: in severe hepatic cirrhosis, bupropion cmax rose by about 70 percent and auc about 3-fold, and half-life was 29 hours vs 19 hours in healthy subjects. sr label table 5 reports bupropion auc about 3.1 times matched controls. a 3-fold exposure increase points to a reduction nearer two-thirds than half. [1][2]
mild hepatic impairment (child-pugh a) also calls for cautionconfirmedboth labels say that for child-pugh 5 to 6, prescribers should 'consider reducing the dose and/or frequency of dosing.' no number is given. the speaker did not address class a, so this is context only. [1][2]

both directions

for the speaker: the labels confirm the core of the claim: in child-pugh b and c, bupropion is labeled for a lower dose. the speaker also grouped the classes the way the labels do, since the labels treat scores 7 to 15 as one band. compared with the 150 mg once-daily starting dose of the xl form, the 150 mg every-other-day ceiling is exactly half.

against: the labels do not describe the change as a proportional reduction. they set a ceiling: 150 mg every other day for xl, and 100 mg a day or 150 mg every other day for sr. both labels give 300 mg a day as the usual target, so the ceiling is roughly a quarter to a third of the usual dose, not half. a listener who halved a 300 mg dose to 150 mg daily would still be at about twice the xl ceiling. the label pharmacokinetics (about 3-fold auc in severe cirrhosis, longer half-life) also point to a bigger cut than half. the real restriction is stricter than the claim, so we rate it undersold rather than wrong.

what this cannot say

the hepatic data in the labels come from small pharmacokinetic studies. in mild to moderate cirrhosis the labels report no statistically significant differences, only more variability, so labeling class b with class c is a conservative regulatory choice rather than a measured 3-fold rise in class b. the labels do not report clinical outcomes such as seizures at these doses. we read two generic dailymed labels (one xl, one sr), not every manufacturer's label or the immediate-release form, and we did not find or read the original cirrhosis pharmacokinetic papers. the clip is short and lacks context: the speaker may have meant half the starting dose, or half the daily frequency, and we cannot tell which.

nothing here is a reason to start, stop or change a medication; those decisions belong with the person taking it and their prescriber.

the medication pages behind this check

sources, each one fetched and read

  1. U.S. National Library of Medicine, DailyMed. Bupropion hydrochloride extended-release tablets (XL), prescribing information, label revised May 2024, setid 129ce80c-0333-873e-e063-6394a90a33e0 What we read there: moderate to severe hepatic impairment (child-pugh 7 to 15): 'the maximum dose is 150 mg every other day'; mild (child-pugh 5 to 6): 'consider reducing the dose and/or frequency of dosing'; target dose '300 mg once daily'; in severe hepatic cirrhosis bupropion cmax and auc increased 'by approximately 70% and 3-fold, respectively', half-life 29 vs 19 hours. Fetched 2026-11-14 (HTTP 200). https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=129ce80c-0333-873e-e063-6394a90a33e0
  2. U.S. National Library of Medicine, DailyMed. Bupropion hydrochloride extended-release tablets (SR), prescribing information, setid 909204fc-ff55-43d9-b9ee-e607ef60965e What we read there: moderate to severe hepatic impairment (child-pugh 7 to 15): 'the maximum dose ... is 100 mg per day or 150 mg every other day'; usual target 300 mg per day as 150 mg twice daily; in severe hepatic cirrhosis bupropion auc about 3.1 times matched healthy controls (table 5). Fetched 2026-11-14 (HTTP 200). https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=909204fc-ff55-43d9-b9ee-e607ef60965e

speakers are described by role, not named. one sentence is quoted under fair use, with attribution and a link to the original at the timestamp; we do not re-host audio or video. nothing on this page is a reason to start, stop or change a medication. if you have the file behind anything marked unverifiable, the research board is where people can answer. adam